Member Info for tqhussain

It certainly is ticking up.
PDSB and NSCI both now to continue growth.

Over $10

IMO I can't see divi coming short term. The cash on hand will be used to drive the like of Glycotest, Proaxsis etc forward.

Only a special divi would be possible through the sale of one of the investments.

Whats changed? our holding value in PDSB is slightly lower than before.

Glycotest is the big fish for me.

As Beckman Group is associated with M A Lawson, who is interested in 22% of NetScientific's issued share capital, the secured loan facility represents a related party transaction in accordance with Rule 13 of the AIM Rules for Companies. The Directors of NetScientific consider, having consulted the Company's nominated adviser, that the terms of the facility are fair and reasonable insofar as its shareholders are concerned.

M A Lawson who is interested in 22% of NSCI...????

Dr. Ilian Iliev is on the board of PDSB so i guess he know better.

Officially no details on the placing have been published.

Agree, I can seen NSCI taking part in the placing.

Great news today, GL

PDSB RNS, raise coming.

https://www.otcdynamics.com/pdsb-pds-biotech-announces-proposed-offering-of-common-stock/

PDSB over $13

https://www.thearmchairtrader.com/netscientific-proaxisis-astra-zeneca-share-price/

This was posted before the Fosun deal. Just shows why Glycotest is so valuable.

Commercialization Opportunities
Glycotest is seeking an equity investment of $10MM to enable commercial launch of the HCC Panel in the US in Q4 2019. Projected third full-year revenue (US only) is $116MM (184K tests sold) in 2022 at 3% penetration of the current US market. The Company is seeking strategic partnerships ex-US, especially in areas of the world like China where over 400K people die of liver cancer annually.

This was mentioned a couple of years back:

Commercialization Opportunities
Glycotest is seeking an equity investment of $10MM to enable commercial launch of the HCC Panel in the US in Q4 2019. Projected third full-year revenue (US only) is $116MM (184K tests sold) in 2022 at 3% penetration of the current US market. The Company is seeking strategic partnerships ex-US, especially in areas of the world like China where over 400K people die of liver cancer annually.

or trials*

I might be wrong but I don't recall seeing Fosun giving Glycotest the 3rd tranche $4m of the funding for their 40% stake. I am guessing the success of the trails is a catalyst for that.

From what I have seen, the study started in May 2019. Study Duration: 30 months ( approximately 24 months accrual + 6 month follow up). Not sure of any impact from covid on the trial.

Glycotest is going through registration phase in China via Fosun pharm. I think registration phase is a step before going commercial.

I know many are thinking this has risen so much but just look how small the market cap is. There is so much value add news to come in the next few months.

p.s. PDSB is up 11% today.

MC only £22m now.

Derampers galore today.

PDSB - Cancer cure (very promising data) and covid vaccine (trials to begin in brazil shortly).
Glycotest – early liver cancer detection - in trials and looking to go commercial this year.
Proaxsis – covid testing (AZ deal announced this week).
Sagetech med – anesthetic gas recycling, which is a big contributor to CO2 gases - in NHS trials and looking to go commercial this year.

https://www.level39.co/vortex-biosciences-liquid-biopsy-for-cancer-diagnosis-announces-experienced-start-up-leader-dr-adrian-kinkaid-as-new-ceo/